Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox
®
New and Old Formulations: Are they Switchable for Millions of Patients?"
Clin Pharmacokinet
.
2019 Jul;58(7):973-975.
doi: 10.1007/s40262-019-00786-w.
Authors
Didier Concordet
1
,
Peggy Gandia
1
,
Jean-Louis Montastruc
2
,
Alain Bousquet-Mélou
1
,
Peter Lees
3
,
Aude A Ferran
1
,
Pierre-Louis Toutain
4
5
Affiliations
1
INTHERES, Université de Toulouse, INRA, ENVT, Toulouse, France.
2
Service de Pharmacologie Médicale et Clinique, Faculté de Médecine, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
3
The Royal Veterinary College, University of London, London, UK.
4
INTHERES, Université de Toulouse, INRA, ENVT, Toulouse, France. pltoutain@wanadoo.fr.
5
The Royal Veterinary College, University of London, London, UK. pltoutain@wanadoo.fr.
PMID:
31187470
PMCID:
PMC6584249
DOI:
10.1007/s40262-019-00786-w
No abstract available
Publication types
Letter
Comment
MeSH terms
Drug Compounding
Humans
Thyroxine*
Substances
Thyroxine